Leuthold Group LLC Boosts Stock Position in United Therapeutics Corporation $UTHR

Leuthold Group LLC lifted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 41.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,672 shares of the biotechnology company’s stock after purchasing an additional 3,126 shares during the period. Leuthold Group LLC’s holdings in United Therapeutics were worth $5,200,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Darwin Global Management Ltd. purchased a new stake in shares of United Therapeutics during the third quarter worth about $317,617,000. Baillie Gifford & Co. purchased a new stake in shares of United Therapeutics during the fourth quarter worth about $157,390,000. UBS Group AG boosted its holdings in shares of United Therapeutics by 45.3% during the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after purchasing an additional 70,445 shares during the period. Soleus Capital Management L.P. boosted its holdings in shares of United Therapeutics by 35.0% during the second quarter. Soleus Capital Management L.P. now owns 209,794 shares of the biotechnology company’s stock worth $60,284,000 after purchasing an additional 54,400 shares during the period. Finally, Legal & General Group Plc boosted its holdings in shares of United Therapeutics by 0.6% during the third quarter. Legal & General Group Plc now owns 199,656 shares of the biotechnology company’s stock worth $83,698,000 after purchasing an additional 1,137 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 14,440 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $472.13, for a total transaction of $6,817,557.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $9,956,712.48. This represents a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 521,413 shares of company stock valued at $289,410,912 in the last ninety days. Insiders own 8.60% of the company’s stock.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for about $5.5 million, trimming her stake by 19%; CFO James Edgemond also sold 10,000 shares for about $5.7 million, reducing his ownership by 34.6%. These sizable insider transactions can make investors cautious about near-term sentiment. Article Title
• Neutral Sentiment: Director Nilda Mesa also sold 258 shares, a smaller transaction that adds to the recent insider selling trend. Article Title
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $660 price target, despite trimming its FY2030 earnings estimate slightly. Broader analyst coverage remains constructive, with a consensus rating of Moderate Buy and a target around $619.42, which may help support the stock. Article Title

Analysts Set New Price Targets

UTHR has been the subject of a number of analyst reports. UBS Group increased their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Oppenheimer increased their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Raymond James Financial initiated coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Price Performance

Shares of UTHR opened at $568.58 on Friday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The company has a 50-day simple moving average of $558.07 and a two-hundred day simple moving average of $507.08. The firm has a market capitalization of $24.13 billion, a PE ratio of 20.99, a price-to-earnings-growth ratio of 1.80 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter last year, the business earned $6.63 earnings per share. The business’s quarterly revenue was down 1.6% on a year-over-year basis. Analysts expect that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.